VivoSeq
Oncology

Advanced Biliary Tract Cancer

2

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Advanced Biliary Tract Cancer is an early-stage landscape with 2 programs across 0 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Lenvatinib Pill,paclitaxel

National Health Research Institutes, Taiwan

Phase 31

Nanvuranlat

J-Pharma Co., Ltd.

Approved
No programs

Analysis

Trial Status

2

clinical trials

Active, not recruiting1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

Phase II Trial of Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment
Active, not recruiting·National Health Research Institutes, Taiwan·Phase 2·NCT05170438·51 enrolled
A Phase 3, Multicenter, Randomized, Open-label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients With Previously Treated Advanced Biliary Tract Cancer
Recruiting·JJ-Pharma Co., Ltd.·Phase 3·NCT07265674·480 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)